A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Prior treatment

• Prior exposure to immune-mediated therapy
• Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
• Ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose.
• Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment
• Active or prior documented autoimmune or inflammatory disease with some exceptions
• Current or prior use of immunosuppressive medication within 14 days with some exceptions

Other illness

• Gastrointestinal bleeding (eg, esophageal varices or ulcer bleeding) within 12 months
• Main portal vein thrombosis (Vp4) as documented on imaging

• Male or female participants
• 18 years and older (Japan-20 years and older)
• Confirmed hepatocellular carcinoma (HCC) based on histopathological findings from tumor tissues. Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods.
• Immunotherapy-naïve
• Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI. For arm 5 only: Have not received any prior systemic therapy for HCC.